Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth.

Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S.

Nat Med. 2001 Nov;7(11):1194-201.

PMID:
11689883
2.
3.

The Id proteins and angiogenesis.

Benezra R, Rafii S, Lyden D.

Oncogene. 2001 Dec 20;20(58):8334-41. Review.

4.

A genetic approach to understanding tumor angiogenesis.

Benezra R, de Candia P, Li H, Romero E, Lyden D, Rafii S, Ruzinova M.

Cold Spring Harb Symp Quant Biol. 2002;67:249-54. No abstract available.

PMID:
12858547
5.

Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells.

Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S.

J Exp Med. 2001 May 7;193(9):1005-14.

6.

Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A.

Kadambi A, Mouta Carreira C, Yun CO, Padera TP, Dolmans DE, Carmeliet P, Fukumura D, Jain RK.

Cancer Res. 2001 Mar 15;61(6):2404-8.

7.

Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth.

Purhonen S, Palm J, Rossi D, Kaskenpää N, Rajantie I, Ylä-Herttuala S, Alitalo K, Weissman IL, Salven P.

Proc Natl Acad Sci U S A. 2008 May 6;105(18):6620-5. doi: 10.1073/pnas.0710516105. Epub 2008 Apr 28.

8.

Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice.

Davidoff AM, Ng CY, Brown P, Leary MA, Spurbeck WW, Zhou J, Horwitz E, Vanin EF, Nienhuis AW.

Clin Cancer Res. 2001 Sep;7(9):2870-9.

9.

Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells.

Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S.

Circ Res. 2001 Feb 2;88(2):167-74.

10.

Bone marrow-derived EP3-expressing stromal cells enhance tumor-associated angiogenesis and tumor growth.

Ogawa Y, Suzuki T, Oikawa A, Hosono K, Kubo H, Amano H, Ito Y, Kitasato H, Hayashi I, Kato T, Sugimoto Y, Narumiya S, Watanabe M, Majima M.

Biochem Biophys Res Commun. 2009 May 15;382(4):720-5. doi: 10.1016/j.bbrc.2009.03.094. Epub 2009 Mar 24.

PMID:
19318087
11.

Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.

Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG.

Cell Growth Differ. 1998 Jan;9(1):49-58.

12.

Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors.

Ruzinova MB, Schoer RA, Gerald W, Egan JE, Pandolfi PP, Rafii S, Manova K, Mittal V, Benezra R.

Cancer Cell. 2003 Oct;4(4):277-89.

13.
14.

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P.

Nat Med. 2002 Aug;8(8):831-40. Epub 2002 Jul 1.

PMID:
12091877
15.

Angiogenesis and prostate cancer: identification of a molecular progression switch.

Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM.

Cancer Res. 2001 Mar 15;61(6):2736-43.

16.

Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.

Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, Breier G.

J Clin Invest. 2002 Mar;109(6):777-85.

17.

Crucial role of inhibitor of DNA binding/differentiation in the vascular endothelial growth factor-induced activation and angiogenic processes of human endothelial cells.

Sakurai D, Tsuchiya N, Yamaguchi A, Okaji Y, Tsuno NH, Kobata T, Takahashi K, Tokunaga K.

J Immunol. 2004 Nov 1;173(9):5801-9. Erratum in: J Immunol. 2005 Mar 15;174(6):3818.

18.

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation.

Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, Carbone DP.

J Immunol. 2005 Jan 1;174(1):215-22.

19.

Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors.

de Candia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, Muller WJ, Rosen N, Benezra R.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12337-42. Epub 2003 Oct 2.

20.

Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis.

Kubo H, Fujiwara T, Jussila L, Hashi H, Ogawa M, Shimizu K, Awane M, Sakai Y, Takabayashi A, Alitalo K, Yamaoka Y, Nishikawa SI.

Blood. 2000 Jul 15;96(2):546-53.

Items per page

Supplemental Content

Write to the Help Desk